To include your compound in the COVID-19 Resource Center, submit it here.

AMG 785 meets osteoporosis endpoint

Amgen Inc. (NASDAQ:AMGN) and partner UCB Group (Euronext:UCB) said subcutaneous AMG 785 met the

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE